Doer Biologics begins patient dosing in phase 2 study of DR10624 to treat metabolic dysfunction-associated steatotic liver disease and MASH: Hangzhou, China Thursday, April 24, 20 ...

MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced that an abstract highlighting data from its Phase 2a clinical ...

MetaVia Inc. ( Nasdaq: MTVA) announced that a late-breaking abstract highlighting Phase 2a data from its DA-1241 program in presumed metabolic dysfunction-associated steatohepatitis (MASH) has been ...

Baqsimi is a nasal spray formulation of glucagon, already widely used as an injectable treatment for hypoglycaemia, which can occur when people with diabetes inadvertently take too much insulin.

Here the authors report that Activin B, expressed in the liver sinusoidal endothelial cells, is involved in glucose homeostasis by regulating hepatic FGF21 production and glucagon sensitivity and ...

NORTHBROOK, IL, USA I April 17, 2025 I Endevica Bio, a privately held company developing first-in-class peptide drug candidates, announced today the dose administration for the first patient in a ...

Dana Schulz is an experienced editor, writer, and content strategist who is just as likely to be crunching the ...